'Orphan drugs' in cardiology: nadolol and quinidine. Journal of cardiovascular medicine (Hagerstown, Md.) [J Cardiovasc Med (Hagerstown)] Journal article | | Title | 'Orphan drugs' in cardiology: nadolol and quinidine. | | Author(s) | Inama G, Durin O, Pedrinazzi C, Berisso MZ, Furlanello F | | Institution | aDivision of Cardiology, Cardiocerebrovascular Department, Ospedale Maggiore, Crema, Italy bDivision of Cardiology, Ospedale Padre Antero Micone, ASL 3, Genova, Italy cArrhythmia and Electrophysiology Center, IRCCS, Policlinico San Donato, San Donato Milanese, Milan, Italy. | | Source | J Cardiovasc Med (Hagerstown) 2009 Oct 13. | | Abstract | The recent withdrawal from the market of nadolol (Corgard; Bristol-Myers Squibb, Sermoneta, Italy) and quinidine polygalacturonate (Ritmocor; Malesci, Bagno A Ripoli, Italy) has been causing clinical problems to many cardiologists and patients, frequently leading to discontinuance of an effective and well-tolerated pharmacological treatment. Nadolol is useful in the treatment of severe and refractory arrhythmias, particularly in some genetically determined ion-channel diseases, such as long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia.Quinidine is still used in refractory atrial fibrillation recurrences. Recent studies have demonstrated the clinical efficacy of quinidine in the treatment of rare genetically determined ion-channel diseases at high risk of sudden death, such as Brugada syndrome and short-QT syndrome.We hope that scientific societies can influence healthcare and pharmaceutical institutions, in order to restore the availability of two cardiovascular drugs that are extremely important in the care of arrhythmic patients. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19829129 |
|
|
| |
Advertise on this site.
| | |
|
